CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disorders

Policy governs coverage and medical necessity of plasma homocysteine testing for screening, evaluation, and management of cardiovascular disease (CVD) and venous thromboembolic (VTE) disorders for BCBSRI Medicare Advantage and Commercial products. It states testing is not covered/ not medically necessary given evidence that lowering homocysteine does not improve outcomes.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disorders

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2024

Next Review Date

Key ActionOnly the ordering physician may be involved in authorization, appeal, or other administrative processes; laboratories may not obtain authorization or bill members if services were unauthorized.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes

2Primary excluded indications (CVD, VTE)

2Plans affected

Coverage Summary

Policy governs coverage and medical necessity of plasma homocysteine testing for screening, evaluation, and management of cardiovascular disease (CVD) and venous thromboembolic (VTE) disorders for BCBSRI Medicare Advantage and Commercial products. Measurement of plasma homocysteine is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products. Effective date: 2024-01-01. Status: CURRENT (policy last reviewed 2024-01-17).

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria

Policy Statement - Coverage Determination

Measurement of plasma homocysteine is not covered / not medically necessary for the following populations and indications:

ALL of the following

Not covered for Medicare Advantage Plans
Not medically necessary for Commercial Products
Indications
- Individuals for cardiovascular disease
- Individuals with venous thromboembolism or risk of venous thromboembolism
Rationale: Large amount of evidence that homocysteine-lowering interventions do not improve health outcomes

Provider Actions

Prior Authorization

Prior authorization not applicable

Policy states prior authorization is not applicable for homocysteine testing; laboratories are not allowed to obtain authorization or participate on behalf of ordering physician; only ordering physician may be involved in authorization/appeal processes. If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

Documentation Required

Authorization/appeal process responsibility

Only the ordering physician shall be involved in authorization, appeal, or other administrative processes related to authorization/medical necessity; use of laboratory representatives or third parties to obtain authorization is a violation and may result in termination from the BCBSRI provider network.

Denial Risk

Claim denial if unauthorized laboratory obtains service

If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

Background & Evidence

Plasma homocysteine has been extensively studied as a risk marker for CVD and VTE and as a target for folate/B‑vitamin lowering therapy. Although observational studies suggested an association between elevated homocysteine and vascular events, randomized controlled trials and meta‑analyses consistently demonstrate that homocysteine‑lowering interventions do not reduce major cardiovascular events and do not reliably reduce VTE risk. Given this large body of evidence, routine homocysteine testing is unlikely to improve health outcomes.

Source	Finding
RCTs/meta-analyses	Homocysteine-lowering treatment does not consistently reduce major cardiovascular events; evidence insufficient to show net health outcome improvement
Cochrane finding	Some reduction in stroke risk reported but considered weak and of uncertain clinical significance

Plasma total homocysteine: Sum of homocysteine and its oxidized forms measured in blood.